Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated by Analysts at StockNews.com
StockNews.com started coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a research note issued to investors on Tuesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Separately, Maxim Group restated a “hold” rating on shares of Galmed Pharmaceuticals in a research note on Friday, April 4th. Check Out […]
StockNews.com started coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a research note issued to investors on Tuesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Separately, Maxim Group restated a “hold” rating on shares of Galmed Pharmaceuticals in a research note on Friday, April 4th. Check Out […]
